Sidvim LifeSciences Private Limited

  Contents Analysis of patent applications Maithri Drugs General information With just 16 new drugs approved in H1 2022, FDA poised for slew of approvals in H2 Aurigene partners with EQRx and announces drug discovery, development and commercialisation Intellectual Property T 2423/19 (OXIDATION OF ORGANIC COMPOUNDS/PeroxyChem) of 25.4.2022 Analysis of patent applications Maithri Drugs Maithri as per their website a company established in 2014 at Hyderabad. The company had filed 39 DMFs, in last two years, each year they filed more than 10 DMFs. They filed 14 CEPs, 30 patent applications.  Last two weeks we analysed DMFs filed by Maithri Drugs and imports of Maithri Drugs. We estimated products under development and probable stages of their development.  This week, we analysed patent applications filed by Maithri drugs and tried to evaluate strengths of their IP. Glimpses of our analysis is published below.  Publication Number Sidvim comments US10544107B2 This patent relates

Contents Analysis of import and export of Maithri Drugs General information The TRIPS Waiver: What Does it Mean to Change the Rules of the Game? Anvisa ordered the withdrawal of the drug Losartan used to treat high blood pressure Intellectual Property T 0752/19 (Ticagrelor, acetylsalicylic acid and a computer program/INTELLECTUAL … of 4.4.2022 Analysis of import and export of Maithri Drugs Maithri as per their website a company established in 2014 at Hyderabad. The company had filed 39 DMFs, in last two years, each year they filed more than 10 DMFs. They filed 14 CEPs, 30 patent applications.  Not much information is available at their website about their R & D capabilities and production facilities.  Very brief analysis of their import and export is presented below. The objective of this analysis is not to derive any commercial conclusions but to try and analyse molecules under development at Maithri Drugs and to assess stage of the development. Imported intermediates

  Contents DMFs filed by Maithri Drugs General information IIT Madras partners with Ministry of AYUSH for AYURTECH 2022 Kerala High Court Directs DPIIT To Contemplate Compulsory Licensing Of Breast Cancer-Saving Drug Ribociclib Intellectual Property Fingolimod (Gilenya) :CAFC decision DMFs filed by Maithri Drugs   Maithri as per their website a company established in 2014 at Hyderabad. The company had filed 39 DMFs, in last two years, each year they filed more than 10 DMFs. They filed 14 CEPs, 30 patent applications.   Not much information is available at their website about their R & D capabilities and production facilities.   Brief of our analysis of their filed DMFs is as below. Subject SIDVIM comments OZANIMOD HYDROCHLORIDE FDA approval was in March 2020 and within 2 years Maithri filed DMF! Generic launch seems difficult before 2029 even in less regulated markets. Maitrhi must have started working on the product before FDA approval. MIRTAZAPINE ANHYDROUS USP This is vanilla ge